Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCD | Q05655 | 7/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 6/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 6/20 | 1.00 |
| ▸ | PRKACA | P17612 | 6/20 | 1.00 |
| ▸ | PRKCG | P05129 | 5/20 | 1.00 |
| ▸ | PRKCB | P05771 | 5/20 | 1.00 |
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCH | P24723 | 5/20 | 1.00 |
| ▸ | PRKCI | P41743 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 5/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 5/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 5/20 | 1.00 |
| ▸ | PRKACG | P22612 | 5/20 | 1.00 |
| ▸ | PRKACB | P22694 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13186235 | 1.00 | PRKCD (1.00) | PRKCDPRKD3PRKCZPRKACAPRKCG | |
| SCHEMBL29968723 | 1.00 | PRKCD (1.00) | PRKCDPRKD3PRKCZPRKACAPRKCG | |
| Calcium SCHEMBL29883592 | 0.99 | PRKCD (0.98) | PRKCDPRKD3PRKCZPRKACAPRKCG | |
| Hydrochloric Acid SCHEMBL6414754 | 0.99 | PRKCD (1.00) | PRKCDPRKD3PRKCZPRKACAPRKCG | |
| Hydrochloric Acid SCHEMBL1064436 | 0.99 | PRKCD (1.00) | PRKCDPRKD3PRKCZPRKACAPRKCG | |
| Hydrochloric Acid SCHEMBL29968524 | 0.99 | PRKCD (1.00) | PRKCDPRKD3PRKCZPRKACAPRKCG | |
| Hydrochloric Acid SCHEMBL15093619 | 0.99 | PRKCD (1.00) | PRKCDPRKD3PRKCZPRKACAPRKCG | |
| Hydrochloric Acid SCHEMBL29353191 | 0.99 | PRKCD (1.00) | PRKCDPRKD3PRKCZPRKACAPRKCG | |
| SCHEMBL23795295 | 0.93 | PRKCD (0.88) | PRKCDPRKD3PRKCZPRKACAPRKCG | |
| SCHEMBL13186226 | 0.93 | PRKCD (0.88) | PRKCDPRKD3PRKCZPRKACAPRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 649 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245668-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-07-25 | — | — | US | claimed |
| US-20210330654-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | US | claimed |
| US-20200121652-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | THE DOSHISHA (JP) | 2020-04-23 | — | — | US | claimed |
| EP-3639855-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | The Doshisha (JP) | 2020-04-22 | — | — | EP | claimed |
| US-20200085804-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2020-03-19 | — | — | US | claimed |
| US-9976172-B2 | Method and apparatus for measuring protein post-translational modification | ICAGEN, INC. (US) | 2018-05-22 | — | — | US | claimed |
| EP-2800973-B1 | METHODS AND COMPOUNDS FOR INCREASING SENSITIVITY OF BOTULINUM ASSAYS | BIOMADISON INC (US) | 2018-05-16 | — | — | EP | claimed |
| US-20160228421-A1 | COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA COMPRISING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| US-20160201111-A1 | Method and Apparatus for Measuring Protein Post-Translational Modification | UNITED STATES GOVERNMENT | 2016-07-14 | — | — | US | claimed |
| US-9006394-B2 | Peptide-presenting surfaces for long-term culture of pluripotent cells | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-04-14 | — | — | US | claimed |
| WO-1999060849-A1 | CRYOPRESERVATION OF HUMAN RED BLOOD CELLS | LIFECELL CORPORATION (US) | 1999-12-02 | — | — | WO | claimed |
| WO-1999004775-A9 | METHOD OF TREATING DOPAMINERGIC AND GABA-NERGIC DISORDERS | ONTOGENY INC (US) | 1999-04-29 | — | — | WO | claimed |
| WO-1999020298-A1 | REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO | ONTOGENY, INC. (US) | 1999-04-29 | — | — | WO | claimed |
| WO-1999010004-A2 | REGULATION OF MUSCLE TISSUES BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO | ONTOGENY, INC. (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1999004775-A2 | METHOD OF TREATING DOPAMINERGIC AND GABA-NERGIC DISORDERS | ONTOGENY, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| WO-1999000117-A2 | NEUROPROTECTIVE METHODS AND REAGENTS | ONTOGENY, INC. (US) | 1999-01-07 | — | — | WO | claimed |
| WO-1997030701-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-08-28 | — | — | WO | claimed |
| EP-0783292-A1 | INHIBITION OF HAIR GROWTH | HANDELMAN, Joseph H. (US) | 1997-07-16 | — | — | EP | claimed |
| US-5554608-A | INHIBITOR OF PROTEIN KINASE C | GILLETTE COMPANY, THE, A DELAWARE CORPORATION | 1996-09-10 | — | — | US | claimed |
| WO-1996009806-A2 | INHIBITION OF HAIR GROWTH | HANDELMAN, JOSEPH, H. (US) | 1996-04-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228421-A1 | COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA COMPRISING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | PRKCD 532/4885PRKD3 820/4885PRKCZ 2472/4885 |
| US-20200085804-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | PRKCD 698/4885PRKD3 744/4885PRKCZ 2440/4885 |
| US-20240245668-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | PRKCD 1209/4885PRKD3 859/4885PRKCZ 2791/4885 |
| US-20200121652-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | TGFB1, CASP3, TGFB2 | PRKCD 332/4885PRKD3 455/4885PRKCZ 299/4885 |
| US-20210330654-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | PRKCD 1209/4885PRKD3 859/4885PRKCZ 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.